Implementation of high-throughput screening for Fabry disease in Toronto dialysis patients
نویسندگان
چکیده
This bill is based on promotion of living-related donations, according to the ministry of health. A closely matched non-related person may only provide an organ out of compassion when a genetically-related donor is unavailable. Cadaveric donation is not among the designated priorities. The edict imposes strict penalties for brokers and those indulging in unsupervised removal, storage and grafting of organs. A federal monitoring authority and evaluation committees in designated institutions have been convened. A donor from their country of origin will have to accompany non-residents if they want to avail of our services [5]. Transplant registry, a nationwide pool of potential donors, a donor card system, as well as allocation of resources for disadvantaged end-stage renal disease (ESRD) patients, donor care and follow-up are planned. Transplant institutions will only be allowed to function if they (and personnel thereof) meet prescribed licensure criteria. Limited experience (28 cadaveric grafts to date), non-existence of a brain-death law and doubts about public approval of cadaveric mode of organ harvesting preclude the optimistic notion of the Transplant Society of Pakistan that a deceased organ donation programme will help save 50 000 lives every year. Pakistani law has global implications because of rampant transplant tourism [6]. It is consistent with contemporary trends [7]. Organ donation by relatives should be portrayed as an act of dignity. I suggest that a sustained strategy of directed donations be adopted, with more effective early identification of a genetically-related donor for each ESRD patient. A strong family setup, and motivation by specialist counsellors, may both play a critical role.
منابع مشابه
Screening of male dialysis patients for fabry disease by plasma globotriaosylsphingosine.
BACKGROUND AND OBJECTIVES Previous reports of Fabry disease screening in dialysis patients indicate that α-galactosidase A activity alone cannot specifically and reliably identify appropriate candidates for genetic testing; a marker for secondary screening is required. Elevated plasma globotriaosylsphingosine is reported to be a hallmark of classic Fabry disease. The purpose of this study was t...
متن کاملResults of a nationwide screening for Anderson-Fabry disease among dialysis patients.
Anderson-Fabry disease is possibly underdiagnosed in patients with end-stage renal disease. Nationwide screening was therefore undertaken for Anderson-Fabry disease among dialysis patients in Austria. Screening for alpha-galactosidase A (AGAL) deficiency was performed by a blood spot test. In patients with a positive screening test, AGAL activity in leukocytes was determined. Individuals with d...
متن کاملFabry dissase from the dentist view
Fabry disease is a rare, inherited disease with lack of the enzyme alpha-galactosidase A (α-Gal) in the cells of the body that participates in the breakdown of fat. The disease begins in early childhood, progresses slowly throughout life and results in severe damage of the kidneys, heart and central nervous system. The disease is life-threatening and if left untreated, death ...
متن کاملFabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice.
Fabry disease (FD) is an X-linked disorder of glycosphingolipid catabolism resulting in the accumulation of glycolipids including globotriaosylceramide in cells of various tissues resulting in end-organ manifestations. Initially, FD is typically characterized by angiokeratoma and recurrent episodes of neuropathic pain in the extremities occurring during childhood or adolescence. Most affected p...
متن کاملSerum Globotriaosylceramide Assay as a Screening Test for Fabry Disease in Patients with ESRD on Maintenance Dialysis in Korea
BACKGROUND/AIMS Fabry disease is an X-linked recessive and progressive disease caused by α-galactosidase A (α-GaL A) deficiency. We sought to assess the prevalence of unrecognized Fabry disease in dialysis-dependent patients and the efficacy of serum globotriaosylceramide (GL3) screening. METHODS A total of 480 patients of 1,230 patients among 17 clinics were enrolled. Serum GL3 levels were m...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 1 شماره
صفحات -
تاریخ انتشار 2008